Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who have given written informed consent to participate in the study.~2. Type 2 Diabetes Mellitus patients either Male or female from 18 - 75 years of age (both inclusive).~3. Patients who are uncontrolled on metformin monotherapy for at least past 4 weeks (1000-1500 mg daily and HbA1c \> 7.5 - 9%).~4. Patients with HbA1C levels within the range \> 7.5% - 9%. (If a past value is available within the last 12 weeks, it would be considered acceptable provided it was obtained after at least 4 weeks of metformin therapy 1000-1500 mg daily).~Exclusion Criteria:~1. Age \> 75 years ; BMI \<22 or \>40 kg/m2~2. Patients who are on Insulin therapy at the time of study entry.~3. Type 1 Diabetes Mellitus patients.~4. Patients with severe renal (creatinine clearance \< 50 ml/min) or hepatic impairment (including pre-treatment ALT or AST \> 3 x ULN).~   Creatinine clearance will be estimated from serum creatinine using Cockcroft-Gault formula (Cockcroft and Gault, 1976)~5. Patients with contraindications as mentioned in the Summary of Product Characteristics (SPCs) for vildagliptin, metformin, glimepiride, vildagliptin plus metformin and glimiperide plus metformin.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A: Vildagliptin plus metformin (Type: EXPERIMENTAL): Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
- Group B: Glimepiride plus metformin (Type: ACTIVE_COMPARATOR): Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).